Dersleri yüzünden oldukça stresli bir ruh haline sikiş hikayeleri bürünüp özel matematik dersinden önce rahatlayabilmek için amatör pornolar kendisini yatak odasına kapatan genç adam telefonundan porno resimleri açtığı porno filmini keyifle seyir ederek yatağını mobil porno okşar ruh dinlendirici olduğunu iddia ettikleri özel sex resim bir masaj salonunda çalışan genç masör hem sağlık hem de huzur sikiş için gelip masaj yaptıracak olan kadını gördüğünde porn nutku tutulur tüm gün boyu seksi lezbiyenleri sikiş dikizleyerek onları en savunmasız anlarında fotoğraflayan azılı erkek lavaboya geçerek fotoğraflara bakıp koca yarağını keyifle okşamaya başlar
Reach Us
+1-947-333-4405
GET THE APP
Significance Of HER2 Genetic Heterogeneity Detected By Fluorescence In Situ Hybridization Analysis In Invasive Ductal Breast Carcinoma | 28260
ISSN: 2161-0681
Journal of Clinical & Experimental Pathology
Open Access
Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.
Breast cancer is the most common malignancy in women of all ethnicities. Standard treatment involves surgical resection;
pathologic analyses that includes morphologic, immunohistochemistry (IHC) and Fluorescence In Situ Hybridization
(FISH) analysis to determine ER, PR and HER2 parameters in the tumor. The HER2 gene (17q11.2-12) is amplified in 20%
of invasive breast cancers. Patients with tumor positive-HER2 gene amplification are eligible for adjuvant chemotherapy with
Trastuzumab (Herceptin) resulting in longer survival. Studies have shown that 40% of breast tumors show genetic heterogeneity
(GH) as per ASCO/CAP (2013) criteria. Breast tumors with an IHC score of 2+ qualify for FISH testing to rule out HER2
gene amplification and if positive, patients are eligible for Herceptin treatment. GH is defined as the presence of >5% and
<50% of 20 tumor cells showing HER2-amplification. The 40% of breast tumors that show GH pose an unresolved dilemma
in treatment. Our aim is to establish the clinical significance of HER2 GH in breast cancer. Data is correlated with patient
demographics, histological tumor type and stage, IHC scores, treatment regimen and morbidity to determine if GH has an
impact on treatment modality. These outcomes include differences in survival (Kaplan-Meyer survival curves) and morbidity
from the treatment (cardiomyopathy). Our hope is to determine whether a systematic study of outcomes among patients with
HER2 GH with or without equivocal FISH results will address reconsiderations of treatment guidelines for these patients.
Biography
K H Ramesh did his PhD in Human Cancer Cytogenetics from Bangalore University, India. He trained under the guidance of world renowned Geneticist Avery
Sandberg, MD at Roswell Park Cancer Institute, Buffalo, USA. He is Board Certified in Clinical Cytogenetics; currently a Diplomate of the American Board of
Medical Genetics and Genomics and Fellow of the American College of Medical Genetics and Genomics. At present he is the Director of Cancer CytoGenomics
and Associate Professor of Pathology at Montefiore Medical Center and Albert Einstein College of Medicine, Bronx, USA. He has over 25 years of experience in
Human Cancer Genetics.
Relevant Topics
Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals